This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

On donanemab, younger people with fewer tangles benefitted the most. On lecanemab, too, people with the fewest tangles improved most on CDR-SB. In the DIAN prevention trial, eight years of ...

According to the latest study on tau-transgenic mice, methylene blue, a drug in clinical trials for frontotemporal dementia (FTD) and Alzheimer's disease (AD), stops decline in its tracks—but only ...

The largest Alzheimer’s GWAS yet has netted 42 new risk loci. The haul, described in a preprint on medRxiv, comes from an enormous collaborative effort by Alzheimer’s geneticists, with 354 authors.

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

The world did not end today as predicted, but unfortunately we have to report that development of another potential drug did. Allon Therapeutics Inc. announced 19 December that its drug candidate ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...